Overview

• US hemp wellness firm's Q1 revenue fell 11% yr/yr on lower sales volume due to restrictive regulations

• Adjusted EBITDA loss narrowed, helped by lower operating expenses

• Company completed debt restructuring to strengthen financial position

Outlook

• Company expects gross margin improvement in the second half of 2026

• Company remains focused on expense management and operational efficiency to achieve profitability

• CV Sciences sees opportunities for growth through strategic acquisitions in current market environment

Result Drivers

• REGULATORY IMPACT - Co said lower sales volume was driven by restrictive regulations at the federal level and in certain states

• NEW PRODUCT CONTRIBUTION - 43% of net revenue in Q1 came from products launched since January 2023, per co

• COST CONTROL - Reduced operating expenses by 13.3% yr/yr, which helped narrow adjusted EBITDA loss

Company press release: ID:nACSVGSmga

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.